MBS-2320 is under clinical development by Istesso and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MBS-2320’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MBS-2320 is under development for the treatment of rheumatoid arthritis, ulcerative colitis, multiple myeloma and autoimmune disorders. It is administered through oral route. It is a new molecular entity.
Istesso formerly known as Modern Biosciences, a subsidiary of IP Group Plc is a pharmaceutical company that offers drug development services. The company provides sources late-stage discovery projects from conducts early proof-of-principle clinical studies, academic institutions, and provides out-licensing services. It develops novel therapeutic agents for the treatment of chronic inflammatory and autoimmune disorders. Istesso offers its project development services through outsourcing the early development work to contract research organizations and research institutions. The company caters its services to the pharmaceutical and biotechnology industry. It serves research institutions, and healthcare professional. Istessois headquartered in London, the UK.
For a complete picture of MBS-2320’s drug-specific PTSR and LoA scores, buy the report here.